Prognostic value of osteopontin expression in breast cancer: A meta-analysis

Xu,Ying-Yi; Zhang,Ya-Ya; Lu,Wei-Feng; Mi,Yan-Jun; Chen,Yu-Qiang

doi:10.3892/mco.2014.480

Prognostic value of osteopontin expression in breast cancer: A meta-analysis

Authors:
- Ying-Yi Xu
- Ya-Ya Zhang
- Wei-Feng Lu
- Yan-Jun Mi
- Yu-Qiang Chen
View Affiliations

Affiliations: Department of Oncology, Chenggong Hospital Affiliated to Xiamen University, No. 174 Hospital of People's Liberation Army, Xiamen 361003, P.R. China, Department of Vascular Surgery, Zhongshan Hospital, Xiamen 361003, P.R. China
Published online on: December 22, 2014 https://doi.org/10.3892/mco.2014.480
Pages: 357-362

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteopontin (OPN) has been implicated in tumor development and progression over the last few years. However, the prognostic value of OPN overexpression in patients with breast cancer remains controversial. We performed a meta‑analysis to investigate the association of OPN expression in the tumor with the clinicopathological characteristics and survival of breast cancer patients. A total of 8 studies met the inclusion criteria and were entered in the meta‑analysis. The data analysis demonstrated that OPN expression was positively associated with lymph node metastasis [pooled odds ratio = 2.026, 95% confidence interval (CI): 1.199‑3.425, P=0.008, random‑effects model]. we also found that OPN expression was positively associated with overall survival [hazard ratio (HR) = 3.69, 95% CI: 1.45‑9.42, P=0.000, random‑effects model) and disease‑free survival (pooled HR=2.40, 95% CI: 1.27‑4.55, P=0.007, fixed‑effects model). Based on the results of this study, we concluded that OPN overexpression in the tumor is a candidate positive prognostic biomarker for breast cancer patients.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Furger KA, Menon RK, Tuck AB, Bramwell VH and Chambers AF: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 1:621–632. 2001. View Article : Google Scholar : PubMed/NCBI
3	Denhardt DT and Guo X: Osteopontin: a protein with diverse functions. FASEB J. 7:1475–1482. 1993.PubMed/NCBI
4	Brown LF, Papadopoulos-Sergiou A, Berse B, et al: Osteopontin expression and distribution in human carcinomas. Am J Pathol. 145:610–623. 1994.PubMed/NCBI
5	Agrawal D, Chen T, Irby R, et al: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 94:513–521. 2002. View Article : Google Scholar : PubMed/NCBI
6	Coppola D, Szabo M, Boulware D, et al: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI
7	Tuck AB and Chambers AF: The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 6:419–429. 2001. View Article : Google Scholar : PubMed/NCBI
8	Tuck AB, Chambers AF and Allan AL: Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem. 102:859–868. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tuck AB, O'Malley FP, Singhal H, et al: Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 79:502–508. 1998. View Article : Google Scholar : PubMed/NCBI
10	Singhal H, Bautista DS, Tonkin KS, et al: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res. 3:605–611. 1997.PubMed/NCBI
11	Bellahcène A and Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 146:95–100. 1995.PubMed/NCBI
12	Bramwell VH, Doig GS, Tuck AB, et al: Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 12:3337–3343. 2006. View Article : Google Scholar : PubMed/NCBI
13	Chang J, Clark GM, Allred DC, Mohsin S, Chamness G and Elledge RM: Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 97:545–553. 2003. View Article : Google Scholar : PubMed/NCBI
14	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
15	de Silva Rudland S, Martin L, Roshanlall C, et al: Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res. 12:1192–1200. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kim YW, Park YK, Lee J, Ko SW and Yang MH: Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci. 13:652–657. 1998. View Article : Google Scholar : PubMed/NCBI
17	Rudland PS, Platt-Higgins A, El-Tanani M, et al: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 62:3417–3427. 2002.PubMed/NCBI
18	Pang H, Lu H, Song H, et al: Prognostic values of osteopontin-c, E-cadherin and beta-catenin in breast cancer. Cancer Epidemiol. 37:985–992. 2013. View Article : Google Scholar : PubMed/NCBI
19	Wang X, Chao L, Ma G, et al: Increased expression of osteopontin in patients with triple-negative breast cancer. Eur J Clin Invest. 38:438–446. 2008. View Article : Google Scholar : PubMed/NCBI
20	Stewart LA and Parmar MK: Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 341:418–422. 1993. View Article : Google Scholar : PubMed/NCBI
21	Liu LY, Wang M, Ma ZB, et al: The role of adiponectin in breast cancer: a meta-analysis. PLoS One. 8:e731832013. View Article : Google Scholar : PubMed/NCBI
22	Lum DW, Perel P, Hingorani AD and Holmes MV: CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One. 8:e766482013. View Article : Google Scholar : PubMed/NCBI
23	Qu Q, Mao Y, Fei XC and Shen KW: The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One. 8:e826502013. View Article : Google Scholar : PubMed/NCBI
24	Zhang Z, Ni C, Chen W, et al: Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer. 14:492014. View Article : Google Scholar : PubMed/NCBI
25	Ribeiro-Silva A and Oliveira da Costa JP: Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study. Int J Biol Markers. 23:154–160. 2008.PubMed/NCBI
26	Allan AL, George R, Vantyghem SA, et al: Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 169:233–246. 2006. View Article : Google Scholar : PubMed/NCBI
27	Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2:563–572. 2002. View Article : Google Scholar : PubMed/NCBI
28	Tuck AB, Arsenault DM, O'Malley FP, et al: Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene. 18:4237–4246. 1999. View Article : Google Scholar : PubMed/NCBI
29	Dai J, Li B, Shi J, et al: A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother. 59:355–366. 2010. View Article : Google Scholar : PubMed/NCBI
30	Tuck AB, Hota C, Wilson SM and Chambers AF: Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene. 22:1198–1205. 2003. View Article : Google Scholar : PubMed/NCBI
31	Wang X, Chao L, Ma G, et al: Primary breast carcinoma: association of mammographic calcifications with osteopontin expression. Radiology. 254:69–78. 2010. View Article : Google Scholar : PubMed/NCBI